secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-061548
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics Q3 net loss $20.1M ($0.45/diluted); cash $159.9M; hematuria resolution data at ASN
--------------------------------------------------------------------------------

- Net loss of $20.1M ($0.45 per diluted share) vs $24.7M ($0.91) in Q3 2022.
- Cash, cash equivalents and securities $159.9M; cash burn $67.0M in nine months.
- Phase 2b OLE eGFR and proteinuria data expected Q1 2024; pivotal Phase 3 ORIGIN 3 enrolling.
- At ASN Kidney Week: 80% of atacicept patients achieved hematuria resolution vs 5% placebo.
- Enrollment of Phase 3 ORIGIN 3 estimated to complete H2 2024; topline data H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000095017023061548/0000950170-23-061548-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000095017023061548/vera-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-061548

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer